TI
RNAC icon

Trexquant Investment’s Cartesian Therapeutics RNAC Stock Holding History

Trexquant Investment’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$428K Buy
+41,046
New +$304K ﹤0.01% 1679
2017
Q4 		– Sell
-641
Closed -$351K – 1229
2017
Q3 		$351K Buy
641
+80
+14% +$42.5K 0.09% 405
2017
Q2 		$334K Buy
+561
New +$248K 0.09% 409

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Trexquant Investment's RNAC Position: Q2 2026 in Review

Trexquant Investment opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 41,046 shares worth $428K. The stake represents ﹤0.01% of the portfolio and ranks #1679 among its holdings. This is a return to the name: Trexquant Investment previously reported a position in RNAC as recently as Q3 2017.

Trexquant Investment first reported a position in RNAC in Q2 2017 and has held it in 3 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Trexquant Investment held 41,046 shares of Cartesian Therapeutics worth $428K as of Q2 2026.
  • Cartesian Therapeutics was a new Trexquant Investment position in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Trexquant Investment's portfolio in Q2 2026, its #1679 holding.
  • Trexquant Investment first reported a position in Cartesian Therapeutics in Q2 2017 and has held it in 3 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.